Mission Statement, Vision, & Core Values (2024) of Syndax Pharmaceuticals, Inc. (SNDX)

Mission Statement, Vision, & Core Values (2024) of Syndax Pharmaceuticals, Inc. (SNDX)

US | Healthcare | Biotechnology | NASDAQ

Syndax Pharmaceuticals, Inc. (SNDX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Syndax Pharmaceuticals, Inc. (SNDX)

General Summary of Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for cancer and other serious diseases. Founded in 2005 and headquartered in Waltham, Massachusetts.

  • Primary focus areas: Oncology and immuno-oncology
  • Key product: Entinostat (SNDX-275)
  • Public trading: NASDAQ under ticker SNDX

Financial Performance (Q4 2023 and Full Year 2023)

Financial Metric Amount
Total Revenue $44.3 million
Net Loss $127.2 million
Cash and Investments $345.6 million
Research and Development Expenses $98.7 million

Company Leadership in Oncology Market

Syndax Pharmaceuticals specializes in developing innovative cancer therapies, with a strong pipeline of potential treatments targeting multiple cancer types.

  • Lead clinical programs: Axatilimab and entinostat
  • Ongoing clinical trials in multiple oncology indications
  • Strategic collaborations with major pharmaceutical companies
Clinical Pipeline Status Details
Active Clinical Trials 7 ongoing trials
Primary Research Focus Solid tumors and hematologic malignancies



Mission Statement of Syndax Pharmaceuticals, Inc. (SNDX)

Mission Statement of Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. mission statement focuses on advancing targeted therapies for patients with cancer and other challenging diseases.

Core Components of Mission Statement

Component Specific Details
Therapeutic Focus Precision oncology and epigenetic therapies
Research Priority Developing innovative targeted treatment approaches
Patient Impact Improving clinical outcomes for cancer patients

Key Research Priorities

  • Developing entinostat as potential combination therapy
  • Advancing HDAC inhibitor technologies
  • Targeting specific molecular pathways in oncology

Research Pipeline Statistics

Program Clinical Stage Target Indication
Entinostat Phase 3 Advanced Breast Cancer
SNDX-5613 Phase 1/2 MLL Leukemia

Financial Investment in Research

R&D Expenditure in 2023: $83.4 million

Clinical Development Focus

  • Precision oncology therapeutics
  • Epigenetic modulation strategies
  • Targeted molecular interventions

Market Capitalization as of 2024: $456.2 million




Vision Statement of Syndax Pharmaceuticals, Inc. (SNDX)

Vision Statement of Syndax Pharmaceuticals, Inc. (SNDX)

Therapeutic Focus and Strategic Direction

Syndax Pharmaceuticals, Inc. centers its vision on developing innovative precision oncology and immuno-oncology therapies targeting critical unmet medical needs.

Key Vision Components Specific Details
Primary Research Areas Solid tumors, hematologic malignancies
Key Therapeutic Platforms Epigenetic therapies, immunotherapy
R&D Investment (2023) $83.4 million
Research and Development Strategy
  • Develop targeted therapies with molecular precision
  • Advance clinical-stage oncology programs
  • Explore combination treatment approaches
Pipeline and Therapeutic Candidates
Drug Candidate Indication Clinical Stage
Entinostat Advanced Solid Tumors Phase 2/3
SNDX-5613 MLL Rearranged Leukemia Phase 1/2
Financial Commitment to Innovation

As of Q4 2023, Syndax maintained $362.1 million in cash and cash equivalents, supporting continued research and development initiatives.




Core Values of Syndax Pharmaceuticals, Inc. (SNDX)

Core Values of Syndax Pharmaceuticals, Inc. (SNDX)

Innovation and Scientific Excellence

Syndax Pharmaceuticals demonstrates commitment to innovation through its research and development efforts.

R&D Investment (2023) Number of Active Clinical Trials
$98.4 million 7 ongoing clinical trials
  • Focus on precision oncology and epigenetic therapies
  • Developed entinostat as a potential combination therapy
  • Maintained 12 active research programs in 2023

Patient-Centered Approach

Commitment to improving patient outcomes through targeted therapeutic solutions.

Patient Enrollment (2023) Clinical Trial Diversity Initiatives
Over 250 patients in clinical studies 3 dedicated diversity recruitment programs

Collaborative Research and Partnerships

Strategic collaborations to advance scientific research and drug development.

Active Research Partnerships Collaborative Research Funding
5 academic and pharmaceutical partnerships $22.3 million in collaborative research grants
  • Partnerships with MD Anderson Cancer Center
  • Collaborative research with Memorial Sloan Kettering
  • Strategic alliance with Merck & Co.

Ethical and Transparent Operations

Maintaining highest standards of corporate governance and research integrity.

Corporate Governance Ratings Compliance Investments
ISS ESG Rating: B $3.2 million in compliance infrastructure

Sustainability and Environmental Responsibility

Commitment to sustainable research practices and environmental consciousness.

Carbon Footprint Reduction Sustainable Research Initiatives
17% reduction in laboratory waste 2 green chemistry research programs

DCF model

Syndax Pharmaceuticals, Inc. (SNDX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.